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 As a contribution to the public health authorities in planning prophylactic and therapeutic vaccine strategies,
we describe the prevalence of human papillomavirus (HPV) types in women  presenting abnormal cytological
results in Pap smear screening tests in the Federal District, Central Brazil. We studied 129 cervical scraping
samples from women whose cytological tests showed either pre-neoplastic or neoplastic lesions. Amplification of
HPV DNA was performed by polymerase chain reaction using consensus primers MY09 and MY11 followed by
identification of isolates by restriction fragment length polymorphism. We detected HPV DNA in 62% of the samples,
including HPV-16 in 43.8%, HPV-58 in 12.5%, HPV-31 in 10%, HPV-53 in 6.3%, each of HPV-18 and HPV-33 in
3.8% of the isolates. Other types (HPV-35, -52, -66, -CP8304, -6, -11, and -CP8061) were less frequent (= or < 2.5%
each). The prevalence of HPV-58 was relatively higher in this population than in data in South America, but similar
to results obtained in other studies in Latin America, Europe, and Eastern Asia. Case-control studies need to be
carried out to establish the association between the prevalence of HPV types – specially the less frequent high-risk
types – and cervical cancer.
Key words: human papillomavirus (HPV) - genotypes - prevalence - HPV-58 - cervical  lesion - Brazil
In contrast to what is observed in developed countries,
cervical cancer mortality in Brazil is still high. Studies on
historical series show that this rate has not changed since
1985. The frequency of deaths and expected new cases
for 2002 were 4005 and 17,600, respectively, which
corresponds to mortality and incidence rates of 4.49/
100,000 women and 19.82/100,000 women, respectively
(Brasil 2002).
The chronic infection by certain types of human
papillomavirus (HPV) is definitely related to the incidence
of cervical cancer (Lorincz et al. 1992, IARC 1995) and the
HPVs -16, -18, -31, -33, -35, -45, -51, -52, and -58 can now
be considered as cervical carcinogenic agents (Muñoz
2000). Squamous carcinomas and adenocarcinomas are
the most frequent cervical neoplasias, and may develop
from intraepithelial lesions, easily detected in preventive
cytological exams (Sherman et al. 1994).
The classification of HPVs in types is based on the
analysis of the nucleotide sequence of the L1 gene (LANL
1997). From more than one hundred HPVs already
identified, over 40 mucosotrophic types were isolated from
anogenital, orogenital or ororespiratory mucosal lesions
(Bernard et al. 1994, zur Hausen & Villiers 1994, LANL
1997). The mucosotrophic HPVs are classified in low and
high risk-types according to the possibility of developing
malignant lesions (Mansur 2001).
The large number of HPV sequences lead to the
generation of a phylogenetic tree of the papillomavirus
family, based on the L1 consensus primer region. This
tree includes the five papillomaviruses supergroups (A-
E). Mucosal or genital HPVs are included in supergroup
A. Other supergroups comprise HPVs that infect human
skin (B) or other vertebrates (C, D, E, S) (LANL 1997).
According to studies carried out in various countries
by the International Association for Research in Cancer
(IARC), the most prevalent reported high-risk HPV types,
which infect the uterine cervix, are: HPV-16 (53%), HPV-
18 (15%), HPV-45 (9%), HPV-31 (6%), and HPV-33 (3%)
(Muñoz 2000). Lower prevalence of other phylogenetically
related types is also found (Meyer et al. 1998).
Reports on the prevalence of genotypes indicate that
HPV-16 is the most prevalent (Bosch et al. 1995,  Muñoz
2000). Nevertheless, the frequency of other high-risk types
may vary according to geographic, demographic and
clinical-pathological factors (Lai et al. 1999,  Hwang 1999,
Lo et al. 2001) and may also be influenced by the methods
used for detection (Qu et al. 1997, Meyer et al. 1998).
Phases I and II human vaccine trials against HPV are
underway or at the planning stage. One difficulty in
developing a vaccine is determining which types of HPV
to include (Hagensee 1999), since geographical variations
in the prevalence of high-risk types are observed (Giuliano
et al. 2001). The aim of our study is to describe the
prevalence of the different HPV types in women with pre-
neoplastic and neoplastic lesions of the cervix, in the
Federal District, Central Brazil. These data may assist the
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public health authorities in planning prophylactic and
therapeutic strategies to prevent cervical cancer.
MATERIALS AND METHODS
Population - From October 1998 to August 2001, 159
outpatients were recruited from gynecology clinics in three
public hospitals in the Federal District. The criterion for
selection was a cytological report within the current year
of cervical intraepithelial neoplasia (CIN 1, CIN 2 or CIN
3), squamous cell carcinoma (SCC), adenocarcinoma
(ADENO), atypical squamous or glandular cells of
undetermined significance (ASCUS or AGCUS) and
cytological alterations suggesting HPV infection (HPV).
Patients who were  referred for cervical biopsies or topical
therapy, after the cytological reports, were not included
in our study.
All subjects were informed about the methodology
and objectives of the research and signed a consent form.
The physicians also registered social, demographical,
epidemiological, clinical, and laboratorial data on a
structured questionnaire. The Committee on Human
Research Ethics granted prior approval to this research
project.
Cervical specimens - Epithelial cells, collected from
the cervical surface by scraping with a nylon brush, were
transferred to a vial containing 5 ml of TE buffer, TRIS
(Life Technologies, Gibco BRL) 10 mM pH 7.5 and EDTA
(Sigma Chemical Co.) 1 mM pH 8.0, and stored at 4oC to
8oC before DNA extraction.
Extraction and precipitation of total DNA - Samples
were centrifuged at 2500 g for 5 min and the pellet re-
suspended in 1 ml of  TE buffer, followed by digestion
with 200 µg/ml proteinase K (Gibco) for 2 to 4 h at 55oC.
DNA was extracted by phenol-chloroform  (VETEC) as
described by Sambrook et al. (1989). Total DNA was
precipitated by 100% ethanol (Reagen) and 5 M NaCl
(Sigma). After incubation for 30 min at -80°C, the vials
were centrifuged at 10,000 g for 15 min. The DNA pellet
was washed with 70% ethanol, dried and re-suspended in
TE buffer. Samples were stored at -80°C.  Whenever
samples showed no amplification, other DNA extraction
methods were used (Margall et al. 1993, Peyton & Wheller
1994, Villa et al. 2000).
Detection of HPV DNA by PCR (polymerase chain
reaction) - For the detection of HPV DNA, we used the
consensus primers MY09 (20 nM) (Gibco) and MY11 (20
nM) (Gibco) (Manos et al. 1989), specific for the L1 ORF
region of HPV, 2.5 mM of dNTPs (Gibco) and 2 U of Taq
polymerase (Gibco). The primers pCO3 (Gibco) and pCO4
(Gibco), specific for the amplification of a 110 base pairs
(bp) fragment of the β-globin gene, were used as a control
of the DNA extraction (Bernard et al. 1994). For
standardizing the PCR protocol we used, as positive
controls, suspensions of HeLa and SiHa cells naturally
infected with HPV-18 and HPV-16, respectively, and kindly
supplied by the Ludwig Institute for Cancer Research,
São Paulo Branch, Brazil. Both distilled water and cervical
samples from women with normal cytological reports were
used as negative controls. Thirty-nine cycles of
amplification were conducted in a MJ Research PTC-100
thermocycler as previously described (Manos et al. 1989).
Samples were submitted to electrophoresis on 1%
agarose gel, followed by 10 mg/ml ethidium bromide
(Sigma) staining for the analysis of the amplified products.
Specimens were considered HPV DNA positive if they
came within the range of 450 bp, when compared to a 100
bp ladder marker, included in each gel (Manos et al. 1989).
2.5. HPV typing - HPV DNA positive samples were
typed by restriction fragment length polymorphism
(RFLP). The products generated by MY09/MY11 primers
were digested by the following enzymes: Bam HI, Dde I,
Hae III, Hinf I, Pst I, Rsa I, and Sau 3AI (New England
Biolabs Inc.). The pattern of length polymorphism for
each sample was analyzed by electrophoresis on 8%
polyacrylamide (Gibco) gels. The eletrophoretic profile of
each sample was compared to the prototypes previously
described (Bernard et al. 1994).
Automated sequencing was used to define the HPV
type present in some of the samples that could not be
characterized by RFLP. The amplified HPV segments were
sequenced automatically by the Taq Dye-terminator
method either in a Megabace System (Amersham-
Pharmacia) or in an ABI 377 DNA sequencer (Applied
Biosystems). Both primers, MY09 and MY11, were used
for sequencing each of these samples, generating forward
and reverse sequences that could be aligned. Similarity
analysis of generated sequences was performed by Basic
Local Alignment Search Tool Analysis (BLAST) programs
(Altschul et al. 1997) provided by the National Center for
Biotechnology Information (http://www.ncbi.nlm.
nih.gov).
Statistical analysis - A data bank was generated and
analyzed in EPI-Info, 6.04d, from the Centers of Diseases
Control and Prevention (CDC). Statistical analysis was
also performed by SAS system for frequency, means,
logistic procedures and odds ratios estimates. The level
of significance of tests (p) was set at 0.05.
RESULTS
One hundred and fifty-nine samples were collected in
three public hospitals in the Federal District.  Thirty
samples (19%) had to be excluded from our study because
PCR products for the β-globin and HPV genes were
negative, even when other DNA extraction methods
(Margall et al. 1993, Peyton & Wheller 1994, Villa et al.
2000) were used .
The 129 samples considered in this work were from
women aged 17 to 73 (mean 37.0; median 35.0). These
women reported that they had had their first intercourse
at the age of 12 to 30 years (mean 17.8; median 17.0), and
periods of 2 to 59 years (mean 16.2; median 14.0) of sexually
active life. The number of sexual partners in the last five
years ranged from 0 to 10 (mean 2.0; median 1.0). When
considering information about sexually transmitted
diseases (STD) informed by 110 subjects, 70% (77/110) of
them answered negatively to diagnosis of STD detected
before the last Pap test and 30% (33/110) answered
positively. In the referred STD group, 54.5% (18/33) had a
previous diagnosis of HPV in cytological screening. As
regards smoking habits, 70.9% (78/110) were nonsmokers
and 29.1% (32/110) indicated that they smoked 3 to 20
cigarettes a day.
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Cytologically diagnosed cervical lesions, were
grouped according to severity, as group 1 (G1), for CIN 2
+ CIN 3 + SCC + ADENO, and group 2 (G2), for ASCUS +
HPV + CIN 1 + AGCUS, and showed the following
distribution: 73.6% (95/129) of G1 and 26.4% (34/129) of
G2. The overall HPV DNA-positive rate was 62.0% (80/
129). The prevalence of HPV in G1 was 66.3% (63/95) and
50% (17/34) in G2 (OR = 1.97; 95% CI = 0.82-4.74, p = 0.09).
The distribution of HPV DNA-positive by cervical lesions
cases, grouped by severity of histological diagnosis, is
shown in Table I.
demonstrated in the literature (IARC 1995, Muñoz 2000).
Brazilian official statistics indicate that cervical cancer is
the third primary neoplasia incident in the Federal District
(Brasil 2002). According to the information provided by
the National STD and AIDS Program (Brasil 2001), genital
condiloma is the most prevalent STD in the Federal
District. But although the data indicates a high incidence
of HPV findings in cervical samples from women with
abnormal cytology reports, no previous study had
described the prevalence of HPV types in this population.
The detection of high-risk and low-risk HPVs by the
hybrid capture II system (Digene Corporation) has been
used by physicians in their private clinics as a tool to
predict the prognosis of cervical lesions in women and in
penile lesions of their sexual partners. Nevertheless, this
method does not produce HPV isolate classification in
types (Poljak et al. 1999).
The overall frequency of HPV DNA in this study (62%)
was lower than that reported by other authors:  76%
(Rabelo-Santos et al. 2003) 78.5% (Lo et al. 2001), 86.2%
(Lai et al. 1999), and 97% (Muñoz 2000), but higher than in
the Chan et al. (1999) and Riethmuller et al. (1999) reports,
which indicate prevalence of 44.3% and 37.8%,
respectively. Cavalcanti et al. (2000) have demonstrated
HPV prevalence raging from 85.6% in low-grade squamous
intraepithelial lesions (LSIL) (Broder 1992) to 55.2% in
SCC in a study of Brazilian women with cervical lesions.
In Germany, Meyer et al. (1998) reported HPV prevalence
of 74% in LSIL patients and in 88% of those with high-
grade squamous intraepithelial lesions (HSIL) (Broder
1992) indicating a prevalence rate of 1.2 (HSIL/LSIL).
Although we could not consider as significant the
association of DNA HPV positiveness in the two groups
of lesions (G1 and G2), our prevalence rate (1.3) is similar
to that reported by Chan et al. (1999).
In single HPV infections, excluding HPV-X, we found
that the most frequent HPV types were HPV-16 (49.2%),
HPV-58 (13.4%), HPV-31 (11.9%), and HPV-53 (6.07%).
HPV-16 is known to be worldwide prevalent (zur Hausen
TABLE I
Distribution of cytological diagnosis
and human papillomavirus (HPV) DNA positiveness, grouped
by severity of lesions
HPV DNA
Cytological positiveness
Group diagnosis n % (%)
G1 a CIN 2 29 22.5
CIN 3 53 41.1
SCC 6 4.6
ADENO 7 5.4
Total (G1) 95 73.6 63 (66.3)
G2 b ASCUS 5   4
AGCUS 3 2.3
HPV 23 17.8
CIN 1 3 2.3
Total  (G2) 34 26.4 17 (50)
Total (G1 + G2) 129 100.0 80 (62)
a: CIN 2 + CIN 3 + SCC + ADENO; b: HPV + CIN 1 + ASCUS
+ AGCUS
Most HPV isolates, 80% (64/80), were typed by RFLP.
Automated sequencing was appropriate to characterize
10% (8/80) of the isolates that could not be typed by RFLP.
The other 10% (8/80) could not be typed by either methods
and were referred to as HPV-X. We have found 13 different
HPV types and HPV-16 was, by far, the most prevalent
both in G1 or G2 (Table II). We also detected co-infection
with two different HPV types in 3.7% (3/80) of the cervical
smears. They occurred in two samples in G1 (HPV-16 +
HPV-CP8061; HPV-53 + HPV-11) and in one in G2 (HPV-16
+ HPV-58). The distribution of HPV types detected in both
groups of lesions is shown in Table II, which does not
include the types detected in co-infections and the ten
HPV-X isolates.
The 11 genotypes isolated in single infections were
classified in the supergroup A (mucosal/genital) following
the phylogenetic tree classification (LANL 1997). A
significant association of group A9 that includes HPV
types -16, -31, -33, -52 and -58  to G1 (CIN 2 + CIN 3 + SCC
+ ADENO) could be detected (OR = 6.39, 95% IC 1.15 -
37.45, p = 0.009).
DISCUSSION
The association between cervical cancer and
persistent infection with specific types of HPV is clearly
      TABLE II
  Human papillomavirus (HPV) types in cervical lesions in
Federal District, Brazil
G1a G2b Total
HPV types n % n % n %
HPV-16 29  56.8 4 25 33 49.2
HPV-18 1 2 2   12.5 3   4.5
HPV-31 8 15.7 0 0 8 11.9
HPV-33 2   3.9 1    6.2 3   4.5
HPV-35 0 0 1    6.2 1   1.5
HPV-52 0 0 1    6.2 1   1.5
HPV-53 2   3.9 2  12.5 4   6.0
HPV-58 7  13.7 2  12.5 9 13.4
HPV-66 1 2 1    6.2 2   3.0
CP8304 0 2 1   6.2 2   3.0
HPV-6b 1 0 1    6.2 1   1.5
Total 51 100 16 100 67 100
a: CIN 2 + CIN 3 + SCC + ADENO; b: HPV + CIN 1 + ASCUS
+ AGCUS
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& Villiers 1994, Bosch et al. 1995, Muñoz 2000) and the
frequency of this type in our samples is similar to data
reported by other authors, who found 47.8% (Rolón et al.
2000) and 48.8% (Lo et al. 2001).
A study conducted in Goiânia, among women with
cervical intraepithelial neoplasia III and invasive cervical
cancer reported a high prevalence (57.1%)  of  HPV-16
(Rabelo-Santos et al. 2003). The authors mentioned that
HPV-16 is actually the most prevalent type in all Brazilian
regions. However, regarding the other  types,  a consi-
derable variation can be observed. Our data showed a
high prevalence of HPV-58 and HPV-31, which seems to
be in accordance with what has been described in the
North and Northeast regions of Brazil (Noronha et al. 1999,
Lorenzato et al. 2000). Lorenzato et al. (2000) reported a
high prevalence (8.2%) of  HPV-58 among women with
cervical lesions compatible with HPV infection in Recife.
Noronha et al. (1999) mentioned that HPV-31, -33 and -58
represented  21.2% of the types identified in  individuals
with CIN grade II or III. However, the population covered
and the methods for virus detection and  typing may vary
among these studies.
The prevalence of HPV-58 reported by other authors
is relatively low compared to HPV-16 and HPV-18 (Eluf-
Neto et al. 1994, Muñoz 2000, Rolón et al. 2000, Lo et al.
2001). In a study of HPV infection at the United States-
Mexico border, HPV-16 was the most common type, but
HPV-58 was the second most prevalent in the Mexican
population, and HPV-18 occupied that position in the
American group (Giuliano et al. 2001). Interestingly, a study
in Spain found that 75% of women who tested sero-
positive for type 58 had been born in a Latin American
country (Touze et al. 2001). HPV-58 was also the second
most common genotype in Japan (Sasagawa et al. 2001)
and in China (23.8%), with a significant trend to increased
prevalence in line with the increasing severity of lesions
(Chan et al. 1999). In Paraguay, which borders of Southern
Brazil, HPV-58 was detected in 2.7% of cervical carcinomas
(Rolón et al. 2000). In our work, the prevalence rate of
HPV-58 in G1 and G2 was 3.5 (p = 0.027). So, different
areas in South America may have significant variations in
the prevalence of different HPV types. Lai et al. (1999)
questioned whether HPV-58 may be partially responsible
for cervical cancer in the older population in East Asia
and urged further investigation on the natural history of
HPV-58-related cervical neoplasias.
Prevalence of HPV-18 (4.5%) and -31 (11.9%) differed
from that reported by Bosch et al. (1995) and Rolón et al.
(2000) who cited prevalence of 14% and 5%, and 10% and
3.5%, respectively. Reports that HPV-18 was more
prevalent in adenocarcinomas (Bosch et al. 1995, van
Muyden et al. 1999, Lo et al. 2001, Sasagawa et al. 2001)
could not be confirmed because insufficient samples of
those lesions were available in the population included in
our work.
In the present study,  infection with A9 phylogenetic
group HPVs (-16, -31, -35, -33, -52, -58) may indicate a less
favorable prognosis for cervical lesions, detected by
cytological screening, since the association of A9 HPVs
to G1 lesions was significant (OR = 6.39%, 95% CI 1.15-
37.42).
The high-risk HPV types detected are compatible to
the cytological diagnosis reports considered for inclusion
criteria. Also, the frequency of high and low risk HPV
types in the pre-malignant and malignant cervical samples,
observed in our study, emphasize the importance of
genotyping for a more accurate prognosis of these lesions.
We wish to emphasize that the prevalence of HPV-58, in
the North, Northeast, and Central Brazil,  should be
considered if prophylactic HPV vaccine trials, based on a
cocktail of a limited number of types, are to be run in this
population. In order to establish associations between
more rare HPV types and the risk of cervical cancer, case-
control studies are recommended.
ACKNOWLEDGMENTS
To Luísa Villa, for technical assistance and John Penney for
reviewing the manuscript.
REFERENCES
Altschul SF, Madden TL, Schäffer AA, Zhang Z, Miller W,
Lipman DJ 1997. Gapped BLAST and PSI-BLAST: a new
generation of protein database search programs. Nucleic
Acid Research 25: 3389-3402.
Bernard HU, Chan SY, Manos MM, Ong CK, Villa LL, Delius
H, Peyton DL, Bauer HM, Wheller CM 1994. Identification
and assessment of known and novel human papillomaviruses
by polymerase chain reaction amplification, restriction
fragment length polymorphisms, nucleotide sequence and
phylogenetic algorithms.  J Infect Dis 170: 1077-1085.
Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM,
Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV
1995. Prevalence of human papillomavirus in cervical cancer:
a worldwide perspective. International biological study on
cervical cancer (IBSCC) study group. J Natl Cancer Inst 87:
796-802.
Brasil, Ministério da Saúde, Coordenação Nacional de DST e
Aids 2001. Available at internet: http://www.aids.gov.Br/
final/dados/DST%20estudos.
Brasil, Ministério da Saúde, Instituto Nacional de Câncer 2002.
Available at: http://www.inca.gov.br/cancer/epidemiologia/
estimativa2002/brasil.html
Broder S 1992. The Bethesda system for reporting cervical/
vaginal cytologic diagnosis-report of the 1991 Bethesda
Workshop. JAMA 267: 1892.
Cavalcanti SM, Zando LG, Passos MR, Oliveira LH 2000.
Epidemiological aspects of human papillomavirus infection
and cervical cancer in Brazil. J Infect 40: 80-87.
Chan PKS, Li WH, Ma WI, Cheung JLK, Cheng AF 1999. High
prevalence of human papillomavirus type 58 in Chinese
women with cervical cancer and pre-cancerous lesions. J
Med Virol 59: 232-238.
Eluf-Neto J, Booth M, Muñoz N, Bosch FX, Meijer CJLM,
Walbooners JMM 1994. Human papillomavirus and invasive
cervical cancer in Brazil. Brit J Cancer 69: 114-119.
Giuliano AR, Papenfuss M, Abrahamsen M, Denmanc C, de
Zapien JG, Henze JLN, Ortega L, de Gala EMB, Stephan J,
Feng J, Baldwin S, Garcia F, Hatch K 2001. Human
papillomavirus infection at the United States-Mexico border:
implications for cervical cancer prevention and control.
Cancer Epidemiol Biomarkers and Prevention 10: 1129-
1136.
Hagensee ME 1999. Human papillomavirus vaccine. Infect Urol
12: 11-19.
Hwang T 1999. Detection and typing of human papillomavirus
DNA by PCR using consensus primers in various cervical
883Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 98(7), October 2003
lesions of Korean women. J Korean Medical Science 24:
593-599.
IARC-International Agency for Research on Cancer 1995.
Monographs on the evaluation of the carcinogenic risks to
humans, vol. 64. Human papillomavirus. International
Agency for Research on Cancer, Lyon.
Lai HG, Sun CA, Yu MH, Chen HJ, Liu HS, Chu TY 1999.
Favorable clinical outcome of cervical cancers infected with
human papillomavirus type 58 and related types. Int J
Cancer (Pred Oncol) 84: 553-557.
LANL-Los Alamos National Laboratory, US 1997. http://hpv-
web.lanl.gov. HPV Sequence Database. HPV Compendium
part I, p. 1- 7.
Lo KWK, Cheung TH, Chung TKH, Wang VW, Poon JS, Li
JCB, Lam P, Wong YF 2001. Clinical and prognostic
significance of human papillomavirus in a Chinese
population of cervical cancers. Gyn  Obst Investigation 51:
202-207.
Lorenzato F, Ho L, Terry G, Singers A, Santos LC, De Lucena
Batista R, Lubambo T 2000. The use of human papil-
lomavirus typing in detection of cervical neoplasia in Recife
(Brazil). Int J Gynecol Cancer 10: 143-150.
Lorincz AT, Reid R, Jenson AB, Greenburg MD, Lancaster W,
Kurman RJ 1992. Human papillomavirus infection of the
cervix. Obst gynecol 79: 328-337.
Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR,
Wolinsky SM 1989. Use of polymerase chain reaction
amplification for the detection of genital human
papillomaviruses. Mol Diagn Human Cancer Cells 7: 209-
214.
Mansur CP 2001. Molecular mechanisms of HPV-associated
oncogenesis. In JC Sterling, SK Tying (eds), Human
Papillomaviruses – Clinical and Scientific Advances, Arnold,
London, p. 24-32.
Margall N, Matias-Guiu X, Chillon M, Coll P, Nunes MAV,
Quilez M, Rabella N, Prats G, Prat J 1993. Detection of
human papillomavirus 16 and 18 DNA in epithelial lesions
of the lower genital tract by in situ hybridization and
polymerase chain reaction: cervical scrapes are not
substitutes for biopsies. J Clin Microbiol 31: 924-930.
Meyer T, Arndt R, Christophers E 1998. Association of rare
papillomavirus types with genital premalignant and
malignant lesions. J Infect Dis 178: 252-255.
Muñoz N 2000. Human papillomavirus and cancer: the
epidemiological evidence. J Clin Virol 19: 1-5.
Noronha V, Mello W, Villa LL, Macedo R, Bisi F, Mota R,
Sassamoto K, Monteiro T, Linhares A 1999. Human
papillomavirus associated with cervix lesions. Rev Soc
Bras Med Trop 32: 235-240.
Peyton CL, Wheller CM 1994. Identification of five novel human
papillomavirus sequences in the New Mexico triethnic
population. J Infect Dis 170: 1089-1092.
Poljak M, Brencic A, Seme K, Vince A, Marin IJ 1999. Com-
parative evaluation of first and second-generation digene
hybrid capture assays for detection of human papil-
lomaviruses associated  with high or intermediate risk for
cervical cancer.  J Clin Microbiol 37: 796-797.
Qu W, Jiang G, Cruz Y, Chang CJ, Ho GYF, Klein RS, Burck
RD 1997. PCR detection of human papillomavirus:
comparison between MY9/MY11 and GP5+/GP6+ primer
systems. J Clin Microbiol 35: 1304-1310.
Rabelo-Santos SH, Zeferino L, Villa LL, Sobrinho JP, Amaral
RG, Magalhães AV 2003. Human papillomavirus prevalence
among women with cervical intraepithelial neoplasia III and
invasive cervical cancer from Goiânia, Brazil. Mem Inst
Oswaldo Cruz 98: 181-184.
Riethmuller D, Gay C, Bertrand X, Bettinger D, Schaak JP,
Carbillet JP, Lassable C, Arveux P, Seilles E 1999. Genital
human papillomavirus infection among women recruited
for cervical cancer screening or for colposcopy determined
by hybrid capture II and polymerase chain reaction. Diag
Molec Pathol 8: 157-164.
Rolón PA, Smith JS, Muñoz N, Kugg SJ, Herrero R, Bosch X,
Lamosas F, Meijer CJLM, Walboomers JMM 2000. Human
papillomavirus infection and invasive cervical cancer in
Paraguay. Int J Cancer 85: 486-491.
Sambrook J, Fritsch EF, Maniatis T 1989. Molecular Cloning:
A Laboratory Manual, 2nd ed., Cold Spring Harbour
Laboratory Press, New York.
Sasagawa T, Basha W, Yanazaki H, Inoue M 2001. High-risk
and multiple human papillomavirus infections associated
with cervical abnormalities in Japanese women. Cancer
Epidemiology Biomarkers & Prevention 10: 45-52.
Sherman ME, Schiffman MH, Lorincz AT, Manos MM, Scott
DR, Kurman RJ, Kiviat NB, Stoler M, Glass AG, Rush BB
1994. Toward objective quality assurance in cervical
cytopathology: correlations of cytopathologic diagnoses
with detection of high-risk Human papillomavirus types.
Am J Clin Pathol 102: 182-187.
Touze A, de Sanjose S, Coursaget  P, Almirall MR, Palacio V,
Meijer CJL, Kornegay J, Bosch FX 2001. Prevalence of
anti-human papillomavirus type 16, 18, 31 and 58 virus-
like particles in women in the general population and in
prostitutes. J Clin Microbiol 39: 4344-4348.
van Muyden RCPA, ter Harmsel BWA, Smedts FMM, Hermans
J, Kuijpers JC, Raikhlin NT, Petrov S, Lebedev A,
Ramaekers FCS, Trimbos JB, Kleter B, Quint WGV 1999.
Detection and typing of Human papillomavirus in cervical
carcinomas in Russian women – A prognostic study. Cancer
85: 2011-2016.
Villa LL, Sichero L, Rahal P, Caballero O, Ferenczy A, Rohan T,
Franco E 2000. Molecular variants of human papillomavirus
types 16 and 18 preferentially associated with cervical
neoplasia. J Gen Virol 81: 2959-2968.
zur Hausen H, Villiers EM 1994. Human papillomaviruses.
Annu Rev Microbiol 48: 427-447.
